Lannett remains optimistic about the “durable” opportunities offered by the respiratory generics and biosimilar insulins in its pipeline, despite a downturn in its financial third quarter ended 31 March 2021 that saw its sales fall by 22.2% to $112.4m.
Acknowledging that turnover was “slightly lower than our expectations,” CEO Tim Crew noted that “adjusted gross margin, adjusted earnings before...







